Agenus' BOT+BAL Combination Shows Durable Survival in MSS Colorectal Cancer
Event summary
- Agenus published peer-reviewed Phase 1b results showing BOT+BAL achieved a median overall survival of 21.2 months in heavily pre-treated MSS metastatic colorectal cancer patients.
- The study included 123 patients with a median of three prior lines of therapy, demonstrating a 21% confirmed objective response rate and a 33% three-year overall survival rate.
- Exploratory biomarker analyses revealed responses in tumors lacking conventional markers of checkpoint sensitivity, supporting BOT's Fc-enhanced immune-priming mechanism.
- No new safety signals were observed with extended follow-up, and lower rates of immune-mediated adverse events were noted with the 1 mg/kg BOT dose.
The big picture
Agenus' results challenge the historical inefficacy of checkpoint immunotherapy in MSS colorectal cancer, a majority of mCRC cases. The data supports the company's Fc-enhanced immune-priming approach, potentially expanding treatment options for patients with limited therapeutic avenues. The findings come as immuno-oncology continues to evolve, with a growing focus on combination therapies and biomarker-driven strategies to overcome resistance in 'cold' tumors.
What we're watching
- Clinical Validation
- Whether the durable survival data will accelerate regulatory discussions for BOT+BAL in later-line MSS colorectal cancer.
- Neoadjuvant Potential
- The pace at which Agenus advances the Phase 3 ROBBIN trial evaluating BOT+BAL in the neoadjuvant setting for MSS colon cancer.
- Competitive Positioning
- How Agenus positions BOT+BAL against emerging therapies targeting immunologically cold tumors.
Related topics